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Objectives: To determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis
associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic in-
flammatory myopathy (IIM) patients.
Methods: Adult patients with confirmed IIM recruited to the EuroMyositis registry (n=1637) from four centres
were investigated for the presence of MSAs/MAAs by radiolabelled-immunoprecipitation, with confirmation of
anti-MDA5 and anti-NXP2 by ELISA. Clinical associations for each autoantibody were calculated for 1483 pa-
tients with a single or no known autoantibody by global linear regression modelling.
Results: MSAs/MAAs were found in 61.5% of patients, with 84.7% of autoantibody positive patients having a
sole specificity, and only three cases (0.2%) having more than one MSA. The most frequently detected auto-
antibody was anti-Jo-1 (18.7%), with a further 21 specificities each found in 0.2–7.9% of patients.
Autoantibodies to Mi-2, SAE, TIF1, NXP2, MDA5, PMScl and the non-Jo-1 tRNA-synthetases were strongly as-
sociated (p < 0.001) with cutaneous involvement. Anti-TIF1 and anti-Mi-2 positive patients had an increased
risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac
involvement (OR 4.15). Interstitial lung disease was strongly associated with the anti-tRNA synthetases, anti-
MDA5, and anti-U1RNP/Sm. Overlap disease was strongly associated with anti-PMScl, anti-Ku, anti-U1RNP/Sm
and anti-Ro60. Absence of MSA/MAA was negatively associated with extra-muscular manifestations.
Conclusions: Myositis autoantibodies are present in the majority of patients with IIM and identify distinct clinical
subsets. Furthermore, MSAs are nearly always mutually exclusive endorsing their credentials as valuable disease
biomarkers.
1. Introduction
The idiopathic inflammatory myopathies (IIMs) polymyositis (PM)
and dermatomyositis (DM) are heterogeneous conditions characterised
by muscle inflammation and weakness, skin rashes and systemic com-
plications including interstitial lung disease (ILD), cardiac involvement
and malignancy. Autoimmune mechanisms have a key role in patho-
genesis, with the majority of patients developing autoantibodies. These
autoantibodies target both nuclear and cytoplasmic components in-
volved in gene transcription, protein translocation and anti-viral re-
sponses. Myositis autoantibodies have traditionally been divided into
myositis-associated (MAA) and myositis-specific (MSA) autoantibody
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subsets with the MAAs typically found in myositis patients with overlap
features of other connective tissue diseases, and the MSAs pre-
dominantly occurring in patients with PM/DM [1,2].
Studies have demonstrated MSA/MAA specificities associate with
distinct clinical subsets of patients [3–6] with sero-clinical classifica-
tions potentially aiding in prompt diagnosis, as well as helping to
predict disease course and response to treatments. However, since
myositis is a rare condition, with an incidence of 11 per 1 million
person years [7], and some MSAs/MAAs occur in less than one percent
of patients, large multicentre cohort studies are required to fully in-
vestigate all of the MSA/MAA associations. Herein, we describe the
prevalence, mutual exclusivity and clinical associations of myositis
autoantibodies in a large European cohort of adult PM and DM patients.
2. Materials and methods
2.1. Patients and sera
Clinical data and serum or plasma samples from 1637 adult prob-
able or definite PM/DM patients according to the Bohan and Peter
criteria [8,9] were available from four large European cohorts recruited
to the EuroMyositis registry (United Kingdom (n= 996), Czech Re-
public (n= 276), Hungary (n= 247) and Sweden (n=118) (Table 1).
Clinical features were recorded using standardised definitions and data
collection as described previously [10] and are shown in
Supplementary Table 1. Written consent to participate and to provide
biological samples was obtained from all subjects according to the
Declaration of Helsinki, under the local ethical committee regulations
of each participating centre.
2.2. Protein immunoprecipitation (IPP)
IPP using [35S]-methionine labelled K562 cell extract was com-
pleted as described previously [11,12] to detect autoantibodies against
23 known autoantigens listed in Table 2. Autoantibodies to Ro52
(TRIM-21), 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR) and cytosolic 5’-nucleotidase 1A could not reliably be de-
tected by this method and were therefore omitted from the analysis.
2.3. NXP2 and MDA5 ELISAs
Where IPP resulted in bands at approximately 140 kDa corre-
sponding to NXP2 or MDA5, samples were analysed by ELISA, as de-
scribed previously [13,14], to confirm the presence or absence of these
specificities.
2.4. Statistical analysis
Statistical analysis was completed using R [15]. Clinical associations
for specific autoantibodies were analysed using 1483 patients that were
either positive for a single autoantibody, or were autoantibody
negative. Each of the major clinical manifestations was analysed using a
generalised linear model using logistic regression. Accordingly, the
clinical features of patients within an autoantibody-defined subgroup
were compared to the remainder of the cohort allowing adjustment for
other autoantibody subgroups. The selection of autoantibodies included
in the final models was based on Akaike information criterion by con-
sidering all possible subsets [16]. Comparison of IPP autoantibody ne-
gative patients against all IPP autoantibody positive patients was per-
formed using 2× 2 contingency tables and Fisher's exact test. Where
applicable, results were expressed as odds ratios (ORs) with 95% con-
fidence intervals (CI).
3. Results
3.1. Autoantibody prevalence and mutual exclusivity
Key demographics are listed in Table 1. IPP screening resulted in the
identification of one or more autoantibodies in 1007 patients (61.5%).
Whilst the majority of these cases had a single autoantibody specificity
(84.7%), 154 patients (15.3%) had autoantibodies targeting multiple
autoantigens; 131 patients had two autoantibodies, 22 patients had
three autoantibodies and one patient had four separate autoantibodies.
When dividing the autoantibodies into MSAs (anti-Jo-1, anti-PL7,
anti-PL12, anti-EJ, anti-OJ, anti-KS, anti-Zo, anti-Ha, anti-SRP, anti-Mi-2,
anti-NXP2, anti-MDA5 and anti-SAE), and MAAs (anti-Ro60, anti-La,
anti-U1RNP/Sm, anti-U3RNP, anti-Ku, anti-PMScl, anti-RNA Pol, AMA
and anti-Topo), only three patients had more than one MSA (Table 2).
Conversely, the occurrence of an MSA with one or more MAAs was
more frequent (98 cases, 6.0% of the total cohort) and multiple MAAs
occurred in a further 53 cases (3.2%) (Table 2, Fig. 1).
3.2. Myositis autoantibodies identify homogeneous clinical subgroups
The association between autoantibody subsets and clinical features
was analysed using linear regression models on data from patients with
a single autoantibody. The clinical features associated with different
MSAs/MAAs are reported below with strong positive associations de-
fined by p < 0.001. Other data including negative associations, sig-
nificance levels as p values, ORs and 95% CIs are summarised in Table 3
(MSAs) and Table 4 (MAAs) (and provided in full in supplementary
Table 1).
3.2.1. Anti-synthetase autoantibodies (ASAs)
The most common autoantibody was anti-Jo-1, present in 18.7% of
cases (306 patients), with the remaining anti-aminoacyl tRNA synthe-
tases (ASAs) (non-Jo-1 ASAs: anti-PL12, anti-PL7, anti-EJ, anti-OJ, anti-
KS and anti-Zo) collectively found in a further 3.5% of patients
(n= 57). No patients had anti-Ha autoantibodies. Due to small num-
bers the non-Jo-1 ASAs were pooled for analysis. Anti-Jo-1 was strongly
associated with interstitial lung disease (ILD), mechanic's hands,
Raynaud's phenomenon (RP), and arthritis. The non-Jo-1 ASAs were
Table 1
Demographics of the four European cohorts studied.
Cohort United Kingdom Czech Republic Hungary Sweden Total
Number 996 276 247 118 1637
Gender Female (%) 67.1 75.5 76.5 69.5 69.6
Male (%) 31.8 20.5 23.5 30.5 29.1
Not Known (%) 1.1 4.0 0.0 0.0 1.3
Median age at onset (IQR) 51 (39–61) 61 (50–68) N/A N/A 52 (39–63)
Ethnic Group Caucasian (%) 81.6 92.8 99.2 98.3 87.4
Non-Caucasian (%) 11.1 0.0 0.0 1.7 6.9
Not Known (%) 7.2 7.2 0.8 0.0 5.7
Subset DM (%) 46.3 56.9 31.2 44.9 45.7
PM (%) 53.7 43.1 68.8 55.1 54.3
N/A: Not available, IQR: Inter-quartile range, DM: Dermatomyositis, PM: Polymyositis.
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strongly associated with the same features (even more so for ILD) apart
from arthritis and strongly associated with periungual erythema.
3.2.2. Anti-SRP
Anti-SRP autoantibodies were present in 2.4% of patients (39 cases)
and were associated with an increased risk of cardiac involvement
(p=0.004, OR 4.15, 95% CI 1.56–11.04).
3.2.3. Anti-Mi-2
Anti-Mi-2 autoantibodies were present in 5.4% of patients (88
cases), and were strongly associated with an increased risk of DM rash
(all subtypes), as well as mechanic's hands, periungual erythema and
dysphagia. Patients with anti-Mi-2 had an increased risk of both cancer-
associated myositis (CAM) (OR 2.5 95% CI 1.35–4.60) or cancer (ever)
(OR 2.06 95% CI 1.16–3.63).
3.2.4. Anti-MDA5
Anti-MDA5 autoantibodies were present in 1.3% of the cohort (21
cases) and were present exclusively in patients with a DM phenotype,
and had a strong association with rash (any) as well as specifically
Gottron's papules, heliotrope rash and periungual erythema. Anti-MDA5
autoantibodies were strongly associated with ILD. Anti-MDA5 auto-
antibodies were the only specificity to be mutually exclusive from any
other MSA and MAA, with no anti-MDA5 positive patients having co-
existing autoantibodies.
3.2.5. Anti-NXP2
Anti-NXP2 autoantibodies were present in 2.3% of patients (38
cases). Anti-NXP2 autoantibodies were strongly associated with rash
(any) and specifically heliotrope rash. There were also significant as-
sociations with V-sign rash, periungual erythema and dysphagia.
3.2.6. Anti-TIF1
Anti-TIF1 autoantibodies were present in 7.0% of patients (114
cases), and were strongly associated with all DM subtypes of rash as
well as periungual erythema and dysphagia. Additionally, patients with
anti-TIF1 autoantibodies were at an increased risk of CAM (OR 4.67
95% CI 2.86–7.63) and cancer (ever) (OR 4.21 95% CI 2.69–6.61). The
significant association between anti-TIF1 autoantibodies and cancer
(ever) only existed for patients ≥50 years of age vs patients< 50 years
of age; OR 3.62 (95% CI 2.09–6.28, p < 0.0001) and OR 1.97 (95% CI
0.56–6.99, p=0.2940), respectively. The significant association be-
tween anti-TIF1 autoantibodies and CAM only existed for patients ≥58
years of age vs patients< 58 years of age; OR 3.94 (95% CI 1.91–8.16,
p < 0.0005) and OR 1.66 (95% CI 0.62–4.40, p=0.3120), respec-
tively.
3.3. 7Anti-SAE
Autoantibodies to SAE were present in 2.6% of patients (42 cases)
and were strongly associated with rash (any), all subtypes of rash and
periungual erythema.
3.4. MAAs
MAAs were collectively present in 22.5% of patients, with anti-
PMScl (7.9%), anti-Ro60 (7.0%) and anti-U1RNP/Sm (7.6%) being the
most prevalent, and the remaining specificities (anti-Ku, anti-La, anti-
U3, anti-RNA Pol, anti-Topo and AMAs) occurring in less than 2.5% of
patients. Since 38.1% of MAA positive patients had dual specificities,
only anti-PMScl, anti-Ku, anti-Ro60, anti-U1RNP/Sm and anti-RNAP-I/
III were present in sufficient numbers to allow statistical analysis. All of
these autoantibodies were strongly associated with CTD-overlap con-
ditions. Anti-U1RNP/Sm and anti-PMScl were all strongly associated
with RP, ILD and dysphagia. Additionally, anti-PMScl autoantibodies
were strongly associated with presence of rash (any), mechanic's hands,
Gottron's rash and periungual erythema. Other significant associations
are shown in Table 4.
Table 2
Autoantibody Frequency and co-existence with another autoantibody in the total cohort of 1673 patients.
Autoantigen
specificity1
Autoantibody
frequency n (%)
Co-Existing Autoantibody
None MSA MAA
Jo-1 PL7 PL12 EJ OJ KS Zo Ha SRP Mi-2 MDA5 NXP2 TIF1 SAE PMScl Ku Ro60 La snRNP Other
Jo-1 306 (18.7) 245 1 4 38 13 15 5
PL7 22 (1.3) 57 (3.5) 20 2
PL12 12 (0.7) 10 1 1
EJ 5 (0.3) 2 1 2
OJ 10 (0.6) 7 (1) 1 2
KS 3 (0.2) 1 1 1
Zo 5 (0.3) 5
Ha 0 (0.0) 0
SRP 39 (2.4) 38 1
Mi-2 88 (5.4) 84 2 3
MDA5 21 (1.3) 21
NXP2 38 (2.3) 32 2 3 1 2
TIF1 114 (7.0) 105 (1) 3 5 2
SAE 42 (2.6) 41 (1)
PMScl 129 (7.9) 119 1 7 2 1
Ku 24 (1.5) 13 (4) (1) (1) (2) (1) 2 3
Ro60 114 (7.0) 19 (38) (2) (1) (2) (2) (3) (3) (7) (2) 30 19 5
La 37 (2.3) 1 (13) (1) (2) (30) 2 0
U1RNP/Sm 124 (7.6) 65 (15) (1) (2) (1) (3) (5) (1) (3) (19) (2) 18
Other 54 (3.3) 28 (5) (2) (2) (5) 18 1
1Jo-1: histidyl-tRNA-synthetase, PL7: threonyl-tRNA-synthetase, PL12: alanyl-tRNA-synthetase, EJ: glycyl-tRNA-synthetase, OJ: isoleucyl-tRNA-synthetase, KS: as-
paraginyl-tRNA-synthetase, Zo: phenylalanyl-tRNA-synthetase, Ha tyrosyl-tRNA synthetase, SRP: signal recognition particle, Mi-2: nucleosome-remodelling deace-
tyalse complex, MDA5: melanoma differentiation-associated protein 5, NXP2: nuclear matrix protein 2, TIF1: transcriptional intermediary factor 1 alpha and/or
gamma subunits, SAE: small ubiquitin-like modifier activating enzyme, PM/Scl: nucleolar macromolecular complex, Ku: DNA-binding nuclear protein complex,
Ro60: SSA/Ro60, La: La/SSB, U1RNP/Sm: small nuclear RNA U1RNP and/or Sm subunits. Other includes U3RNP: small nuclear RNA U3 subunit, RNA Pol: RNA
polymerase I/II/III, M2 mitochondrial antigen and topoisomerase I. Only three patients (0.18%) had more than one MSA (anti-Jo-1 coexistent with anti-OJ, anti-KS
coexistent with anti-TIF1 and anti-KS coexistent with anti-SAE). Anti-PmScl is the only MAA that is not detected at all with a MSA.
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3.5. No identifiable autoantibody
There was no identifiable MSA or MAA in 627 patients (38.3% of
the cohort). Analysis of the clinical associations of this group, in com-
parison to the collective MSA/MAA positive group, resulted in several
negative associations (Table 5) strongly so with mechanics' hands, ILD,
periungual erythema, presence of rash (any), Gottron's rash, heliotrope
rash, dysphagia, CTD-overlap conditions and RP.
4. Discussion
We have shown that autoantibodies specific or associated with
myositis as identified by IPP are present in the majority (61.5%) of
patients of IIM using four large combined cohorts of patients.
Furthermore, MSAs and MAAs identify important clinical phenotypes
beyond traditional subgroups of PM/DM. Moreover, the autoantibody
negative group was different from the autoantibody positive in having
less frequent extra-muscular manifestations. MSAs were found in 42.9%
of the total cohort and in those where further clinical details were
available were mostly associated with cutaneous features, apart from
anti-Jo-1 and anti-SRP that were associated with arthritis and cardiac
involvement respectively. Additionally, anti-TIF1 and anti-Mi-2 were
associated with cancer and anti-tRNA synthetases and anti-MDA5 with
lung disease. MAAs were found in 22.5% of the total cohort and in
contrast to MSAs identified patients with CTD/overlap disease, de-
monstrating a key difference between what is defined as a MSA versus a
MAA. The autoantibody negative patients had none of the above
characteristics likely reflecting a commonality of myositis in all sub-
groups given the requirement of fulfilling Bohan and Peter criteria for
inclusion in the study.
The MSA/MAAs identified in this mostly Caucasian population were
present in expected frequencies with anti-Jo-1 (18.7%) the most
common [1]. By contrast, Japanese and Chinese cohorts have higher
frequencies of anti-MDA5 (15–36.6% vs 1.3%) and ASAs (27.6–40.0%
vs 22.2%) [17]. Studies of juvenile myositis populations including our
own using the identical method of autoantibody detection report higher
frequencies of anti-TIF1 (18–32% vs 7.0%), anti-NXP2 (15–20% vs
2.3%) and anti-MDA5 (6% vs 1.3%) [12,18]. Notably ASA are much less
frequent in juvenile disease (2–4% vs 22.2%) [12,18]. Why these au-
toantibodies occur at different frequencies in various cohorts remains
unknown, but the data suggest that age, genetics and environmental
exposures, may all have key roles in determining autoantibody speci-
ficity [5,19].
Another notable finding was that the concurrent presence of more
than one MSA in a single patient was extremely uncommon. Whilst
9.4% of our combined cohort had more than one autoantibody, only
three cases (0.2%) had more than one MSA. By contrast, MAAs co-ex-
isted with other myositis autoantibodies more frequently, although anti-
PMScl was not present with another MSA. Other studies using IPP to
test myositis cohorts have had similar findings with MSAs co-existing in
less than 0.2% of cases [20,21], in contrast to data from cohorts
screened using other assays where co-existence of MSAs occurs in up to
Fig. 1. Prevalence and inter-relationship of autoantibodies in myositis. At least one identifiable MSA or MAA is present in 61.5% of myositis patients and myositis
specific autoantibodies together with anti-PMScl very rarely overlap.
Z. Betteridge, et al. Journal of Autoimmunity 101 (2019) 48–55
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16.7% of cases [20,22,23], likely reflecting differences in sensitivity
and specificities between assays. Nonetheless, the detection of more
than one MSA or a MSA with anti-PMScl by IPP in an individual patient
is rare. A limitation of our study is the absence of results for anti-Ro52
autoantibodies, an MAA that is detected frequently in patients with
PM/DM, and may confer adverse prognostic importance [24,25].
Autoantibodies to Mi-2, TIF1, MDA5, SAE and NXP2 have tradi-
tionally been regarded as ‘DM’ autoantibodies due to their associations
with cutaneous features [3] which is consistent with our findings.
However, we had insufficient data to investigate reported associations
between anti-MDA5 and cutaneous ulceration [26] or anti-NXP2 and
calcinosis [27] which is a limitation of our study. Consistent with
previous studies non-Jo-1 ASAs were associated with cutaneous in-
volvement [28] whereas anti-Jo-1 was associated with arthritis [29].
The association between IIM and malignancy is well established
with a meta-analysis demonstrating a relative risk of 4.66 for DM and
1.75 for PM [30]. The risk is even higher in patients with anti-TIF1 with
one meta-analysis describing an OR of 27.26 (95% CI: 6.59–112.82)
[31]. In agreement, we found anti-TIF1 to be strongly associated with
malignancy, however at a lower OR in terms of both cancer ever (OR
4.21) and CAM (OR 4.67) that was comparable to an adult American
myositis cohort (OR 4.2 for CAM), indicating that patient demographics
may have an influence on malignancy risk [32]. We also found a po-
sitive association between anti-Mi-2 and cancer contrary to previous
findings [33]. One other study has reported a positive association be-
tween cancer and autoantibodies to the N-Terminus of Mi-2 [34], and
therefore further investigation ideally including autoantibody reactivity
to Mi-2 epitopes is warranted.
A second MSA that has been associated with cancer is anti-NXP2.
Malignancy was initially reported in 37.5% of Japanese adult anti-NXP2
Table 3
Clinical Associations of myositis specific autoantibodies.
Positive Clinical Associations Negative Clinical Associations
Clinical Association p value OR 95% CI Clinical Association p value OR 95% CI
Anti-Jo-1 n=245 ILD <0.001 13.80 9.84–19.36 V-Sign Rash = 0.003 0.37 0.19–0.72
Mechanic's hands < 0.001 8.81 5.59–13.89 Shawl Sign Rash = 0.047 0.46 0.21–0.99
Raynaud's < 0.001 2.30 1.62–3.26 Heliotrope Rash = 0.024 0.63 0.42–0.94
Arthritis < 0.001 2.04 1.52–2.73
Periungual Erythema =0.017 1.81 1.11–2.95
Non Jo-1 ASA n=45 Periungual Erythema <0.001 64.39 8.44–491.12 Muscle Weakness = 0.002 0.23 0.10–0.58
ILD <0.001 20.58 10.09–41.94
Raynaud's < 0.001 7.24 3.07–17.10
Mechanic's hands < 0.001 5.88 2.52–13.76
Rash (any DM)1 = 0.038 1.89 1.03–3.44
Anti-SRP n=38 Cardiac Involvement = 0.004 4.15 1.56–11.04 Gottron's Rash = 0.017 0.09 0.01–0.65
Arthritis = 0.028 0.37 0.15–0.90
Anti-Mi-2 n=84 Rash (any DM) <0.001 23.71 10.82–51.99 CTD-Overlap = 0.030 0.11 0.02–0.81
Gottron's Rash < 0.001 6.12 3.39–10.15
Heliotrope Rash < 0.001 5.64 3.42–9.31
Mechanic's hands < 0.001 5.17 2.71–9.87
Periungual Erythema <0.001 4.63 2.63–8.14
V-Sign Rash < 0.001 4.13 2.33–7.33
Shawl Sign Rash < 0.001 2.87 1.59–5.18
Dysphagia < 0.001 3.17 1.86–5.41
CAM =0.003 2.50 1.35–4.60
Cancer (ever) = 0.013 2.06 1.16–3.63
Anti-MDA5
N=21
Rash (any DM) <0.001 43.12 5.76–322.62 Raised CK =0.038 0.30 0.10–0.93
Periungual Erythema <0.001 13.89 3.78–50.97
Gottron's Rash < 0.001 11.56 3.84–34.74
ILD <0.001 7.54 3.13–18.19
Mechanic's hands = 0.005 5.81 1.71–19.70
Heliotrope Rash < 0.001 5.22 2.08–13.13
Anti-NXP2 Rash (any DM) <0.001 7.70 3.29–17.99
Heliotrope Rash < 0.001 3.92 1.85–8.28
V-Sign Rash = 0.010 3.50 1.34–9.09
Dysphagia = 0.005 3.30 1.44–7.55
Periungual Erythema =0.015 3.10 1.24–7.74
Anti-TIF1 n=105 Rash (any DM) <0.001 42.68 17.22–105.83 Raised CK <0.001 0.26 0.16–0.43
Gottron's Rash < 0.001 19.49 10.44–36.38 CTD-Overlap = 0.029 0.27 0.09–0.88
Heliotrope Rash < 0.001 12.59 7.29–21.77 Muscle Weakness = 0.001 0.30 0.15–0.62
Shawl Sign Rash < 0.001 10.24 5.79–18.12 Arthritis = 0.003 0.46 0.27–0.76
Periungual Erythema <0.001 9.56 5.45–16.77 Raynaud's = 0.034 0.53 0.29–0.95
V-Sign Rash < 0.001 7.80 4.42–13.77
Mechanic's hands < 0.001 6.15 3.44–11.01
CAM <0.001 4.67 2.86–7.63
Cancer (ever) < 0.001 4.21 2.69–6.61
Dysphagia < 0.001 2.62 1.62–4.23
Anti-SAE n=41 Rash (any DM) <0.001 42.04 10.0–175.15 Arthritis = 0.025 0.39 0.17–0.89
Gottron's Rash < 0.001 12.43 5.40–28.59
Periungual Erythema <0.001 15.15 4.93–46.57
Shawl Sign Rash < 0.001 9.56 3.74–24.42
Heliotrope Rash < 0.001 14.80 3.12–35.79
V-Sign Rash < 0.001 5.99 2.38–15.09
Results are shown on an analysis of 1483 patients with either a single MSA or MAA or no identifiable autoantibody on immunoprecipitation. 1Rash (any DM):
presence of any one of heliotrope, Gottron's, shawl sign or V sign dermatomyositis rash. ILD: Interstitial Lung Disease, CTD: Connective Tissue Disease, CK: Creatine
Kinase OR: Odds Ratio, CI: Confidence Interval, CAM: cancer associated myositis.
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positive patients [35], and was found to be strongly associated in a
study on American adult DM patients [32]. However, whilst cancer was
more common in our anti-NXP2 positive group in comparison to the rest
of the cohort (13.5% vs 9.5% for CAM and 17.1% vs 14.2% for cancer-
ever), this did not reach statistical significance. These differences may
partially be explained by differences in methodology; the prevalence of
anti-NXP2 in our cohort was similar to other adult myositis cohorts
screened by IPP [17,36,37], but was significantly lower than the US
cohort assayed by in-vitro IPP [32]. Since multivariate analysis of the
US cohort demonstrated the association between anti-NXP2 and cancer
to be significant only in males, the relatively low number of anti-NXP2
positive males in our cohort (n=11) limited our ability to perform a
comparable analysis.
The reported incidence of cardiac involvement in myositis ranges
from 6 to 75% depending on patient selection, case definitions and
diagnostic testing methods [38]. Whilst initial studies described a cor-
relation between anti-SRP and cardiac involvement [1], subsequent
investigations have been unable to confirm this finding [39,40]. In our
cohort, we found a strong association between anti-SRP and cardiac
involvement, with patients having a four times increased likelihood for
this clinical manifestation.
ILD affects 20–65% of adults with myositis and is associated with a
worse prognosis [41–43]. In agreement with previous studies we found
the ASAs (Jo-1 and non-Jo-1), PMScl and anti-MDA5 to be significantly
associated with ILD, with the non-Jo-1 ASA positive patients having an
even greater risk of lung involvement than the Jo-1 positive patients
[21,44]. Anti-MDA5 autoantibodies have been previously associated
with ILD in both adult and juvenile cohorts [13,45,46], and rapidly
progressive ILD and increased mortality in Eastern Asian patients
[13,26,45,47]. We found anti-MDA5 positive patients to have a 7.5 fold
increased risk of ILD, however lack of details on the severity of ILD
prevented us from studying the association with rapidly progressive
disease, which is a limitation of our study.
Anti-Ku and anti-U1RNP autoantibodies have been associated with
ILD in SSc and MCTD patients [48,49] and previous studies have de-
scribed lung involvement in 82% of anti-Ku positive and 60% of anti-
U1RNP positive myositis cases [50,51]. We also found anti-Ku and
antiU1RNP/Sm to be associated with ILD, although ILD was present in a
lower percentage of cases (41.7% for anti-Ku and 30.2% for anti-
U1RNP/Sm). Also the majority of patients with these autoantibodies
had CTD-overlap and the ILD association may be with the overlap
condition rather than with IIM.
Finally, just under 40% of patients in our cohort had no identifiable
autoantibody, although we did not include testing for anti-HMGCR,
anti-Ro52, or anti-CN1A that are not reliably detected by our im-
munoprecipitation assay. However, 74.4% of these patients had auto-
reactivity to unidentified proteins on immunoprecipitation suggesting
the presence of uncharacterised autoantibodies in at least a subset of
these cases. Interestingly, whilst these patients were a heterogeneous
group, they collectively had a decreased likelihood of overlap disease,
cutaneous involvement, ILD and cardiac manifestations, possibly re-
flecting stronger associations with muscle involvement itself. The lack
of sufficient histology to allow a diagnosis of immune-mediated ne-
crotising myopathy is another limitation of our study.
5. Conclusion
Myositis patients have been divided traditionally into DM and PM,
Table 4
Clinical Associations of myositis associated autoantibodies.
Positive Clinical Associations Negative Clinical Associations
Clinical Association p value OR 95% CI Clinical Association p value OR 95% CI
Anti-PMScl n=119 Mechanic's hands < 0.001 16.34 9.29–28.76 V-Sign Rash = 0.049 0.46 0.21–1.00
CTD-Overlap < 0.001 6.74 4.44–10.22
Raynaud's < 0.001 6.44 3.78–10.98
ILD <0.001 6.28 4.12–9.57
Dysphagia < 0.001 3.70 2.24–6.11
Rash (any DM)1 < 0.001 2.68 1.82–3.95
Periungual Erythema =0.002 2.49 1.39–4.45
Gottron's Rash < 0.001 2.23 1.47–3.40
Anti-Ku n=13 CTD-Overlap < 0.001 9.97 2.63–24.16
Arthritis = 0.009 7.71 1.66–35.90
Raynaud's = 0.013 7.39 1.52–35.92
ILD =0.007 4.90 1.53–15.72
Anti-Ro60 n=19 CTD-Overlap < 0.001 5.42 2.09–14.08
Anti-U1RNP/Sm n=65 CTD-Overlap < 0.001 18.17 10.46–31.57 Gottron's Rash = 0.014 0.31 0.12–0.79
Raynaud's < 0.001 15.21 5.88–39.35 Heliotrope Rash = 0.046 0.44 0.19–0.98
Dysphagia < 0.001 3.37 1.66–6.80
ILD <0.001 2.96 1.67–5.27
Results are shown on an analysis of 1483 patients with either a single MSA or MAA or no identifiable autoantibody on immunoprecipitation. 1Rash (any DM):
presence of any one of heliotrope, Gottron's, shawl sign or V sign dermatomyositis rash. ILD: Interstitial Lung Disease, CTD: Connective Tissue Disease, OR: Odds
Ratio, CI: Confidence Interval.
Table 5
Clinical associations autoantibody negative patients.
Clinical Feature Autoantibody
Positive (%)
Autoantibody
Negative (%)
p value OR 95% CI
Mechanic's hands 31.4 7.1 < 0.001 0.17 0.11–0.25
ILD 39.5 12.2 < 0.001 0.21 0.16–0.28
Periungual
erythema
49.9 19.9 < 0.001 0.25 0.18–0.35
Rash (any DM)1 54.4 33.8 < 0.001 0.43 0.35–0.53
Gottron's rash 44.4 26.6 < 0.001 0.45 0.35–0.58
Dysphagia 45.6 28.4 < 0.001 0.47 0.36–0.62
CTD Overlap 18.4 9.7 < 0.001 0.48 0.35–0.66
Heliotrope rash 41.8 28.5 < 0.001 0.56 0.43–0.71
Raynaud's
phenomenon
47.9 33.8 < 0.001 0.56 0.43–0.71
Cardiac
involvement
12.5 7.5 = 0.018 0.57 0.36–0.91
V-sign rash 37.1 27.4 = 0.008 0.62 0.43–0.88
Shawl sign rash 28.0 19.3 = 0.006 0.64 0.47–0.88
Results are shown on an analysis of the total cohort of 1637 patients comparing
patients with at least one identifiable MSA or MAA on immunoprecipitation
versus autoantibody negative. 1Rash (any DM): presence of any one of helio-
trope, Gottron's, shawl sign or V sign dermatomyositis rash. ILD: Interstitial
Lung Disease, CTD: Connective Tissue Disease, OR: Odds Ratio, CI: Confidence
Interval.
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based on the presence or absence of skin disease. Our results strongly
suggest that autoantibodies may offer a better mechanism for identi-
fying clinically relevant and homogenous patient subgroups, borne out
by recent studies that have included autoantibodies as part of classifi-
cation criteria [6,52]. The strong associations of MSA with specific
clinical features may help to lead to early identification of patients
without classical myopathy features but still at increased risk of po-
tentially life-threatening complications, such as ILD. Further work is
warranted to investigate how autoantibody status may influence man-
agement decisions and a more personalised approach to therapy.
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